Patents by Inventor Rajeev A. Jain

Rajeev A. Jain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230125208
    Abstract: Disclosed herein are pharmaceutical compositions having a mixture of at least one active agent and an ion exchange resin, such that the composition releases about 75% or more of the at least one active agent within about 1 hour as measured by in-vitro dissolution in a USP Apparatus 2 (paddle) at about 50 rpm in about 900 ml 0.1N HCl at about 37° C. and related methods. Also disclosed herein are pharmaceutical compositions having a mixture of a drug susceptible to abuse, a non-opioid analgesic and an ion exchange resin, the composition further including at least one gelling agent and related methods.
    Type: Application
    Filed: December 21, 2022
    Publication date: April 27, 2023
    Inventors: Gerard P. Frunzi, Sibao Chen, Rajeev A. Jain
  • Patent number: 11564918
    Abstract: Disclosed herein are pharmaceutical compositions having a mixture of at least one active agent and an ion exchange resin, such that the composition releases about 75% or more of the at least one active agent within about 1 hour as measured by in-vitro dissolution in a USP Apparatus 2 (paddle) at about 50 rpm in about 900 ml 0.1N HCl at about 37° C. and related methods. Also disclosed herein are pharmaceutical compositions having a mixture of a drug susceptible to abuse, a non-opioid analgesic and an ion exchange resin, the composition further including at least one gelling agent and related methods.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: January 31, 2023
    Assignee: RHODES PHARMACEUTICALS L.P.
    Inventors: Gerard P. Frunzi, Sibao Chen, Rajeev A. Jain
  • Publication number: 20190262334
    Abstract: Disclosed herein are pharmaceutical compositions having a mixture of at least one active agent and an ion exchange resin, such that the composition releases about 75% or more of the at least one active agent within about 1 hour as measured by in-vitro dissolution in a USP Apparatus 2 (paddle) at about 50 rpm in about 900 ml 0.1N HCl at about 37° C. and related methods. Also disclosed herein are pharmaceutical compositions having a mixture of a drug susceptible to abuse, a non-opioid analgesic and an ion exchange resin, the composition further including at least one gelling agent and related methods.
    Type: Application
    Filed: October 10, 2017
    Publication date: August 29, 2019
    Inventors: Gerard P. Frunzi, Sibao Chen, Rajeev A. Jain
  • Publication number: 20130011447
    Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 10, 2013
    Inventors: Jon Swanson, Rajeev A. Jain, Robert Hontz, John G. Devane, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary G. Liversidge
  • Patent number: 8293277
    Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.
    Type: Grant
    Filed: June 22, 1999
    Date of Patent: October 23, 2012
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Jon Swanson, Rajeev A. Jain, Robert Hontz, John G. Devane, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary Liversidge
  • Patent number: 8236352
    Abstract: The present invention is directed to nanoparticulate compositions comprising glipizide. The glipizide particles of the composition preferably have an effective average particle size of less than about 2 microns.
    Type: Grant
    Filed: November 5, 2003
    Date of Patent: August 7, 2012
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: H. William Bosch, Niels P. Ryde, Rajeev A. Jain, Jon Swanson, Robert Hontz, John G. Devane, Kenneth Ian Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary G. Liversidge
  • Publication number: 20120114754
    Abstract: Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water-dispersible excipient, wherein the poorly soluble active ingredient particles have an average diameter, prior to inclusion in the dosage form, of less than about 2000 nm. The dosage form of the invention has the advantage of combining rapid presentation and rapid dissolution of the active ingredient in the oral cavity.
    Type: Application
    Filed: November 8, 2011
    Publication date: May 10, 2012
    Inventors: Rajeev A. Jain, Stephen B. RUDDY, Kenneth Iain CUMMING, Maurice Joseph Anthony CLANCY, Janet Elizabeth CODD
  • Publication number: 20110300210
    Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.
    Type: Application
    Filed: May 6, 2011
    Publication date: December 8, 2011
    Inventors: Jon Swanson, Rajeev A. Jain, Robert Hontz, John G. Devane, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary Liversidge
  • Patent number: 7998507
    Abstract: Nanoparticulate compositions comprising at least one poorly soluble MAP kinase inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.
    Type: Grant
    Filed: December 7, 2005
    Date of Patent: August 16, 2011
    Assignee: Elan Pharma International Ltd.
    Inventors: H. William Bosch, Greta G. Cary, Douglas C. Hovey, Rajeev A. Jain, Laura J. Kline, Elaine Merisko-Liversidge, Kevin D. Ostrander, Niels P. Ryde, Stephen B. Ruddy
  • Publication number: 20100062066
    Abstract: A pharmaceutical composition for the oral or parenteral administration of a compound of Formula (I) comprising an oil in water emulsion, wherein the oil phase comprises the free base of or a pharmaceutically acceptable salt thereof of a compound of Formula (I), and one or more surfactants which are soluble in the oil phase and/or the aqueous phase. The emulsion optionally contains one or more excipients that are soluble in the oil phase and/or the aqueous phase, such as pH modifying agents such as buffers, osmolality/tonicity modifying agents, emulsifying agents, water-soluble polymers, and preservatives. The compound of Formula (I) can be formulated as a solid material and stored until needed. Kits for forming the emulsion are provided. Prior to administration, the solid material can be reconstituted in an aqueous medium to form the emulsion.
    Type: Application
    Filed: November 8, 2007
    Publication date: March 11, 2010
    Applicant: Acusphere, Inc
    Inventors: Howard Bernstein, Olinda Carneiro, Rajeev A. Jain, Namrata Pandit, Shveta Rane, Julie Ann Straub
  • Publication number: 20090297619
    Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.
    Type: Application
    Filed: June 11, 2009
    Publication date: December 3, 2009
    Inventors: Jon Swanson, Rajeev A. Jain, Robert Hontz, John G. Devane, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary G. Liversidge
  • Publication number: 20090130213
    Abstract: Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water dispersible excipient, wherein the poorly soluble active ingredient particles have an average diameter, prior to inclusion in the dosage form, or less than about 2000 nm. The dosage form of the invention has the advantage of combining rapid presentation and rapid dissolution of the active ingredient in the oral cavity.
    Type: Application
    Filed: October 31, 2007
    Publication date: May 21, 2009
    Inventors: Rajeev A. Jain, Stephen B. Ruddy, Kenneth lain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd
  • Publication number: 20080248123
    Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.
    Type: Application
    Filed: March 26, 2008
    Publication date: October 9, 2008
    Inventors: Jon Swanson, Rajeev A. Jain, Robert Hontz, John G. Devane, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary Liversidge
  • Publication number: 20080213371
    Abstract: Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water dispersible excipient, wherein the poorly soluble active ingredient particles have an average diameter, prior to inclusion in the dosage form, of less than about 2000 nm. The dosage form of the invention has the advantage of combining rapid presentation and rapid dissolution of the active ingredient in the oral cavity.
    Type: Application
    Filed: February 11, 2008
    Publication date: September 4, 2008
    Inventors: Rajeev A. Jain, Stephen B. Ruddy, Kenneth lain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd
  • Publication number: 20080124393
    Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.
    Type: Application
    Filed: October 31, 2007
    Publication date: May 29, 2008
    Inventors: Jon Swanson, Rajeev A. Jain, Robert Hontz, John G. Devane, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd
  • Publication number: 20040057993
    Abstract: Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water dispersible excipient, wherein the poorly soluble active ingredient particles have an average diameter, prior to inclusion in the dosage form, of less than about 2000 nm. The dosage form of the invention has the advantage of combining rapid presentation and rapid dissolution of the active ingredient in the oral cavity.
    Type: Application
    Filed: September 23, 2003
    Publication date: March 25, 2004
    Applicant: Elan Pharma International Limited
    Inventors: Rajeev A. Jain, Stephen B. Ruddy, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd
  • Publication number: 20040013613
    Abstract: Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water dispersible excipient, wherein the poorly soluble active ingredient particles have an average diameter, prior to inclusion in the dosage form, of less than about 2000 nm. The dosage form of the invention has the advantage of combining rapid presentation and rapid dissolution of the active ingredient in the oral cavity.
    Type: Application
    Filed: January 15, 2003
    Publication date: January 22, 2004
    Inventors: Rajeev A Jain, Stephen B Ruddy, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd
  • Publication number: 20030181411
    Abstract: Nanoparticulate compositions comprising at least one poorly soluble MAP kinase inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.
    Type: Application
    Filed: March 20, 2003
    Publication date: September 25, 2003
    Applicant: Elan Pharma International Ltd.
    Inventors: H. William Bosch, Greta G. Cary, Douglas C. Hovey, Rajeev A. Jain, Laura J. Kline, Elaine Merisko-Liversidge, Kevin D. Ostrander
  • Publication number: 20020012675
    Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.
    Type: Application
    Filed: June 22, 1999
    Publication date: January 31, 2002
    Inventors: RAJEEV A. JAIN, JON SWANSON, ROBERT HONTZ, JOHN DEVANE, KENNETH IAIN CUMMING, MAURICE JOSEPH ANTHONY CLANCY, JANET ELIZABETH CODD
  • Patent number: 6316029
    Abstract: Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water-dispersible excipient, wherein the poorly soluble active ingredient particles have an average diameter, prior to inclusion in the dosage form, of less than about 2000 nm. The dosage form of the invention has the advantage of combining rapid presentation and rapid dissolution of the active ingredient in the oral cavity.
    Type: Grant
    Filed: May 18, 2000
    Date of Patent: November 13, 2001
    Assignee: Flak Pharma International, Ltd.
    Inventors: Rajeev A. Jain, Stephen B. Ruddy, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd